Skip to main content

Pharmacopeial Forum Table of Contents

View the current Pharmacopeial Forum (PF) Table of Contents. Forolder PF tables of contents, visit our archive.

Select from the below links to access PF content. A free resource, PF visitors mustcreate a user name and password.

PF 48(4) Table of Contents Publish date: [July 1, 2022]

Proposed Interim Revision Announcements

USP Monographs

Acetaminophen 1-Jan-2023

Isotretinoin Capsules 1-Jan-2023

Ziprasidone Hydrochloride 1-Jan-2023

NF Monograph

Ammonium Sulfate 1-Jan-2023

In-Process Revision

General Test and Assay Chapters

<581> Vitamin D Assay (USPNF 2023 ISSUE 3)

<601> inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders - Performance Quality Tests (USPNF 2023 ISSUE 3)

<670> Auxiliary Packaging Components (USPNF 2023 ISSUE 3)

<761> Nuclear Magnetic Resonance Spectroscopy (USPNF 2023 ISSUE 3)

General Information Chapters

<1078> Good Manufacturing Practices for Bulk Pharmaceutical Excipients (USPNF 2023 ISSUE 3)

<1079.3> Monitoring Devices - Time, Temperature, and Humidity [NEW] (USPNF 2023 ISSUE 3)

<1094> Capsules - Dissolution Testing and Related Quality Attributes (USPNF 2023 ISSUE 3)

<1118> Monitoring Devices - Time, Temperature, and Humidity (USPNF 2023 ISSUE 3)

<1761> Applications of Nuclear Magnetic Resonance Spectroscopy (USPNF 2023 ISSUE 3)

Reagents, Indicators, and Solutions

Reagent Specifications

Bromelain (USPNF 2023 ISSUE 3)

Guanine Hydrochloride USPNF 2023 ISSUE 2

Methylbenzothiazolone Hydrazone Hydrochloride (USPNF 2023 ISSUE 3)

Alpha Tocopherol [NEW] (USPNF 2023 ISSUE 3)

Water, Deaerated (USPNF 2023 ISSUE 3)

Description and Solubility

Description and Solubility (USPNF 2023 ISSUE 3)

USP Monographs

Chlorhexidine Gluconate and Isopropyl Alcohol Topical Solution [NEW] (USPNF 2023 ISSUE 3)

Clonidine Hydrochloride Compounded Oral Suspension (USPNF 2023 ISSUE 3)

Cyanocobalamin (USPNF 2023 ISSUE 3)

Dabigatran Etexilate Mesylate [NEW] (USPNF 2023 ISSUE 3)

Fentanyl Citrate and Ropivacaine Hydrochloride Compounded Injection (USPNF 2023 ISSUE 3)

Sodium Fluoride F 18 Injection USPNF 2023 ISSUE 2

Gefitinib [NEW] (USPNF 2023 ISSUE 3)

Gefitinib Tablets [NEW] (USPNF 2023 ISSUE 3)

Hydrochlorothiazide (USPNF 2023 ISSUE 3)

Lansoprazole Compounded Oral Suspension (USPNF 2023 ISSUE 3)

Mannitol Compounded Injection [NEW] USPNF 2023 ISSUE 2

Methylprednisolone (USPNF 2023 ISSUE 3)

Nadolol (USPNF 2023 ISSUE 3)

Nadolol Tablets (USPNF 2023 ISSUE 3)

Sodium Bicarbonate Compounded Injection (USPNF 2023 ISSUE 3)

Spironolactone and Hydrochlorothiazide Tablets (USPNF 2023 ISSUE 3)

Tolnaftate (USPNF 2023 ISSUE 3)

Tolnaftate Topical Aerosol (USPNF 2023 ISSUE 3)

Tolnaftate Cream (USPNF 2023 ISSUE 3)

Tolnaftate Topical Powder (USPNF 2023 ISSUE 3)

Tolnaftate Topical Solution (USPNF 2023 ISSUE 3)

Vardenafil Tablets [NEW] (USPNF 2023 ISSUE 3)

NF Monographs

Carrageenan (USPNF 2023 ISSUE 3)

Cetostearyl Alcohol (USPNF 2023 ISSUE 3)

Stimuli to The Revision Process

Consistent Terminology for Advancement of NMR Spectroscopy [NEW]

In Vitro Performance Tests for Continuous Manufacturing: The Impact on the Current Compendial Framework from the Viewpoint of the USP New Advancements in Product Performance Testing Expert Panel [NEW]

In-Vitro Product Performance of Parenteral Drug Products: View of the USP Expert Panel [NEW]